The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...

The advisory committee meeting is an important step in the process of readying boosters for the fall and winter season, but ...

The firm, a prolific backer of drug startups, will use the cash to back companies working on therapeutics, medical devices ...

While updated study results confirmed the drug lowers a target protein, the therapy's effect on clinical outcomes was less ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

The startup’s first prospect is a heart medicine that works differently than the hypertrophic cardiomyopathy drugs developed ...